Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2B | Q02880 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712051 | 0.91 | TOP2B (0.41) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL714008 | 0.88 | KDM4E (0.37) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL712446 | 0.88 | TOP2B (0.42) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL712447 | 0.88 | TOP2B (0.42) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL2532049 | 0.85 | HDAC3 (0.31) | KDM4EALDH1A1LMNA | |
| SCHEMBL12342302 | 0.85 | TOP2B (0.47) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL2108803 | 0.84 | TOP2B (0.47) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL541196 | 0.82 | TOP2B (0.40) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL541195 | 0.82 | TOP2B (0.40) | TOP2BPIK3CGKDM4EALDH1A1LMNA | |
| SCHEMBL541887 | 0.82 | TOP2B (0.43) | TOP2BPIK3CGKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | TOP2B 4619/4885PIK3CG 2429/4885KDM4E 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.